Zydus Lifesciences announces completion of Phase II(a) clinical trial of Usnoflast
Usnoflast, is a “First-in-class” NLRP3 inhibitor to demonstrate proof-of-concept in Phase 2(a) clinical study in ALS patients Usnoflast was well-tolerated ...
Usnoflast, is a “First-in-class” NLRP3 inhibitor to demonstrate proof-of-concept in Phase 2(a) clinical study in ALS patients Usnoflast was well-tolerated ...
